« Return to News | Technology Solutions

Certara releases version 13 of Simcyp Simulator

Wednesday, August 28, 2013 12:37 PM

Certara, a provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through development, has released version 13 of its Simcyp Simulator, which permits the quantitative prediction of drug-drug interactions and pharmacokinetic-pharmacodynamic outcomes in virtual populations.

The latest platform strengthens Simcyp’s position as a provider of translation tools for connecting preclinical ADMET data to clinical outcomes using modeling and simulation.

Simcyp has extended its model repertoire for biologics by incorporating a full physiologically-based pharmacokinetic (PBPK) model for monoclonal antibodies and therapeutic proteins with significant practical applications. In addition, the inclusion of a non-linear plasma protein and red blood cell-binding facility in version 13 addresses a level of complexity regularly needed for modeling in the oncology arena. The integration of a novel sophisticated IVIVC tool to handle in vitro-in vivo correlations of dissolution for various solid oral dosage forms enhances the scope of the simulator in the divisions of formulation and pharmaceutics.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.